PQS Step 14: High Risk Medicines - Anticoagulant Audit

Published: Tue, 11/16/21

PharmaPlus PQS Bitesize Guide Step 14:

16 November 2021

High Risk Medicines - Anticoagulant Audit

Dear Member,

So far we have shared:
STEP 1: Returning unwanted inhalers – Email sent on 31/08/2021
STEP 2: NMS expansion and gateway criteria – Email sent on 1/09/2021

STEP 3: Inhaler technique checks as part of the catch up NMS service – Email sent on 10/09/2021
STEP 4: Staff training requirements – Email sent on 14/09/2021
STEP 5: PCN Leads requirements – Event on 27/09/2021

STEP 6: Infection prevention & control and AMS – Email sent on 27/09/2021

STEP 7: TARGET antibiotic checklist audit – Email sent on 04/10/2021

STEP 8: Aspiration Payment Claim - Email sent on 05/10/2021

STEP 9: PCN Requirements and Flu - Email sent on 12/10/2021

STEP 10: Personalised asthma action plans (PAAPs) and promoting spacer device use in children prescribed pMDIs - email sent on 18/10/2021

STEP 11: Health Inequalities & COVID-19 Vaccination uptake – Email sent 26/10/2021

STEP 12: Weight Management Intervention & Referrals - Email sent 05/11/2021

STEP 13: Patient Safety - Email sent 09/11/2021

Next is:
STEP 14: High Risk Medicines - Anticoagulant Audit

The audit aims to minimise preventable harm from the high-risk medicines – oral anticoagulants, including direct-acting oral anticoagulants (DOACs).

What you need to do:

1. Read through 2017 Specialist Pharmacy Service clinical audit on anticoagulants.
a. Contains essential information on improving safety of those taking anticoagulants.
b. Implement into day-to-day practice the findings and recommendations.

2.   Click here to download the revised anticoagulant safety audit form for 2021/22.
      a.   Over 2 weeks with a minimum of 15 patients or 4 weeks if 15 patients are not achieved within 2 weeks.
      b.   Include all patients including those who have deliveries, live in care homes, etc.

3. Record the start and end date of the audit (required for MYS submission).

4.   You MUST submit your audit results using the snap survey tool accessed via MYS.
      a.   Click on ‘PQS Oral Anticoagulant Safety Audit 2021/22 – upload daily or at the end of the audit period.
      b.   Please note this is a different submission to your overall PQS declaration.
      c.   Do not include any patient identifiable information.

5. Must notify the patients GP where concerns are identified.
a. Must follow up on any actions and document these in the patients PMR to ensure all necessary corrective actions have been taken.

As always, if you require any further support please contact the PharmaPlus team.

Regards,

PharmaPlus

Book Your TRAINING

Pre-Reg Training 2021

Pharma Plus Ltd.

Unit B1-B3, Livingstone Court, 55 Peel Road, Harrow, Middlesex HA37QT

info@pharmaplusltd.co.uk | Tel: 020 8863 3335 | Fax: 020 8863 4144 | www.pharmaplusltd.co.uk

Missed an email? Click here for an archive of our most recent communications!

NOTICE

The information contained in this electronic transmission is protected by privilege (which is not waived), strictly confidential and intended for use only by the addressee. If you receive this electronic transmission by mistake then the dissemination distribution or copying of it is strictly prohibited. In such a case please contact us immediately by telephone or return this electronic transmission.